According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the manufacturing facility of ROLONTIS (eflapegrastim), a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, maintained deficient controls and/or procedures;
- the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration (“FDA”) would approve the ROLONTIS Biologics License Application (the “ROLONTIS BLA”) in its current form;
- Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.